5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol
C22H24FN7O2 — CID 170011125
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol
5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol (PubChem CID 170011125) has the molecular formula C22H24FN7O2 and a molecular weight of 437.48 g/mol. Its IUPAC name is 5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol.
Molecular Properties
| Compound Name | 5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol |
|---|---|
| PubChem CID | 170011125 |
| Molecular Formula | C22H24FN7O2 |
| Molecular Weight | 437.48 g/mol |
| Exact Mass | 437.20 |
| IUPAC Name | 5-[6-[(3R,5R)-3,5-dimethylpiperazin-1-yl]-4-methoxypyrido[2,3-d]pyrimidin-2-yl]-7-fluoro-2-methylindazol-6-ol |
| SMILES | COc1nc(-c2cc3cn(C)nc3c(F)c2O)nc2ncc(N3C[C@@H](C)N[C@H](C)C3)cc12 |
| InChI | InChI=1S/C22H24FN7O2/c1-11-8-30(9-12(2)25-11)14-6-16-20(24-7-14)26-21(27-22(16)32-4)15-5-13-10-29(3)28-18(13)17(23)19(15)31/h5-7,10-12,25,31H,8-9H2,1-4H3/t11-,12-/m1/s1 |
| InChIKey | PTMRQYFGAZYZSN-VXGBXAGGSA-N |
| XLogP | 2.62 |
| TPSA | 101.22 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 437.48 |
| LogP ≤ 5 | 2.62 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170011125 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.